Skip to main content

Advanced Malignancy

10
Pipeline Programs
9
Companies
10
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
10
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 12 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
3 programs
3
AMG 228Phase 11 trial
AMG 337Phase 11 trial
Arm 1- Dose EscalationPhase 11 trial
Active Trials
NCT02437916Terminated30Est. Dec 2016
NCT01253707Completed111Est. Dec 2016
NCT00858377Completed95Est. Apr 2019
Kartos Therapeutics
Kartos TherapeuticsCA - Redwood City
3 programs
3
AMG 232Phase 1
AMG 232Phase 11 trial
AMG 232Phase 11 trial
Active Trials
NCT01723020Completed107Est. Sep 2017
NCT02016729Completed36Est. Jul 2017
Adcytherix
AdcytherixFrance - Marseille
1 program
1
ADCX-020Phase 11 trial
Active Trials
NCT07238075Recruiting290Est. Nov 2029
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
AMG 232Phase 1
Biocorp
BiocorpFrance - Issoire
1 program
1
AMG 820Phase 1
Innovent Biologics
Innovent BiologicsChina - Jiangsu
1 program
1
IBI318Phase 11 trial
Active Trials
NCT03875157Completed103Est. Feb 2023
GSK
GSKLONDON, United Kingdom
1 program
AMG 232PHASE_11 trial
Active Trials
NCT02110355Completed31Est. Dec 2018
SynDevRx
SynDevRxMA - Cambridge
1 program
SDX-7320PHASE_11 trial
Active Trials
NCT02743637Completed32Est. Dec 2019
Chia Tai TianQing Pharmaceutical Group
1 program
AnlotinibPHASE_2Small Molecule1 trial
Active Trials
NCT04216082Completed93Est. Aug 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Chia Tai TianQing Pharmaceutical GroupAnlotinib
AdcytherixADCX-020
Innovent BiologicsIBI318
SynDevRxSDX-7320
AmgenAMG 228
GSKAMG 232
Kartos TherapeuticsAMG 232
Kartos TherapeuticsAMG 232
AmgenAMG 337
AmgenArm 1- Dose Escalation

Clinical Trials (10)

Total enrollment: 928 patients across 10 trials

A Study of Anlotinib in Subjects With Advanced Malignancy

Start: Aug 2013Est. completion: Aug 201593 patients
Phase 2Completed

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

Start: Feb 2026Est. completion: Nov 2029290 patients
Phase 1Recruiting

Study of IBI318 in Participants With Advanced Malignancies

Start: Apr 2019Est. completion: Feb 2023103 patients
Phase 1Completed

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

Start: Feb 2016Est. completion: Dec 201932 patients
Phase 1Completed

Safety Study of AMG 228 to Treat Solid Tumors

Start: Apr 2015Est. completion: Dec 201630 patients
Phase 1Terminated

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Start: Dec 2014Est. completion: Dec 201831 patients
Phase 1Completed

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Start: Apr 2014Est. completion: Jul 201736 patients
Phase 1Completed

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

Start: Dec 2012Est. completion: Sep 2017107 patients
Phase 1Completed

A Study of AMG 337 in Subjects With Advanced Solid Tumors

Start: Dec 2010Est. completion: Dec 2016111 patients
Phase 1Completed
NCT00858377AmgenArm 1- Dose Escalation

A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors

Start: Aug 2009Est. completion: Apr 201995 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 928 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.